A detailed history of Coldstream Capital Management Inc transactions in Biogen Inc. stock. As of the latest transaction made, Coldstream Capital Management Inc holds 2,697 shares of BIIB stock, worth $468,711. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,697
Previous 2,262 19.23%
Holding current value
$468,711
Previous $487,000 28.34%
% of portfolio
0.02%
Previous 0.01%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$190.52 - $236.72 $82,876 - $102,973
435 Added 19.23%
2,697 $625,000
Q1 2024

May 13, 2024

SELL
$212.02 - $267.71 $4,240 - $5,354
-20 Reduced 0.88%
2,262 $487,000
Q4 2023

Feb 09, 2024

BUY
$222.59 - $267.94 $74,122 - $89,224
333 Added 17.09%
2,282 $590,000
Q3 2023

Nov 02, 2023

SELL
$253.3 - $285.89 $61,045 - $68,899
-241 Reduced 11.0%
1,949 $500,000
Q2 2023

Aug 03, 2023

BUY
$275.25 - $318.06 $11,010 - $12,722
40 Added 1.86%
2,190 $623,000
Q1 2023

May 15, 2023

SELL
$256.56 - $292.34 $5,131 - $5,846
-20 Reduced 0.92%
2,150 $597,000
Q4 2022

Jan 10, 2023

BUY
$252.44 - $306.72 $42,409 - $51,528
168 Added 8.39%
2,170 $0
Q2 2022

Aug 08, 2022

BUY
$187.54 - $223.02 $101,459 - $120,653
541 Added 37.03%
2,002 $408,000
Q2 2022

Aug 08, 2022

BUY
$187.54 - $223.02 $48,385 - $57,539
258 Added 21.45%
1,461 $298,000
Q1 2022

May 11, 2022

SELL
$193.77 - $244.14 $52,124 - $65,673
-269 Reduced 18.27%
1,203 $253,000
Q4 2021

Feb 11, 2022

BUY
$223.92 - $287.77 $84,641 - $108,777
378 Added 34.55%
1,472 $353,000
Q3 2021

Nov 12, 2021

SELL
$282.99 - $369.05 $21,507 - $28,047
-76 Reduced 6.5%
1,094 $310,000
Q2 2021

Aug 16, 2021

BUY
$259.0 - $414.71 $73,815 - $118,192
285 Added 32.2%
1,170 $405,000
Q1 2021

Jun 16, 2021

SELL
$242.95 - $284.63 $48,347 - $56,641
-199 Reduced 18.36%
885 $248,000
Q4 2020

Feb 16, 2021

BUY
$236.26 - $355.63 $256,105 - $385,502
1,084 New
1,084 $265,000
Q3 2020

Nov 16, 2020

SELL
$264.77 - $305.71 $204,402 - $236,008
-772 Closed
0 $0
Q2 2020

Aug 12, 2020

SELL
$258.66 - $342.55 $11,381 - $15,072
-44 Reduced 5.39%
772 $207,000
Q1 2020

May 27, 2020

SELL
$268.85 - $341.04 $47,586 - $60,364
-177 Reduced 17.82%
816 $258,000
Q4 2019

Feb 13, 2020

BUY
$220.06 - $304.07 $21,785 - $30,102
99 Added 11.07%
993 $294,000
Q3 2019

Nov 15, 2019

BUY
$217.44 - $243.88 $194,391 - $218,028
894 New
894 $208,000
Q4 2018

Feb 26, 2019

SELL
$278.5 - $352.75 $206,647 - $261,740
-742 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$293.51 - $383.83 $217,784 - $284,801
742 New
742 $262,000
Q1 2018

May 16, 2018

SELL
$260.13 - $367.91 $256,748 - $363,127
-987 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$307.64 - $344.58 $69,219 - $77,530
225 Added 29.53%
987 $314,000
Q3 2017

Nov 15, 2017

BUY
$281.15 - $329.69 $214,236 - $251,223
762
762 $239,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Coldstream Capital Management Inc Portfolio

Follow Coldstream Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Coldstream Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Coldstream Capital Management Inc with notifications on news.